Comparison of pathologic characteristics and mammographic findings between triple negative breast cancer and non-triple negative breast cancer

doi:10.3877/cma.j.issn.1674-0807.2013.05.006

Abstract

Abstract:

Objective

To evaluate the pathologic characteristics and mammographic findings of triple negative breast cancer (TNBC).

Methods

We retrospectively analyzed the clinical data of 1102 women who had been pathologically diagnosed with primary breast cancer in our hospital, including: TNBC group [n=174,ER(-)/PR(-)/HER2(-)], ER(-)/PR(-)/HER-2(+) group (n=183), ER(+)/PR(-)/HER-2(-)group (n=65), ER(+)/PR(+)/HER-2(-)group (n=583) and ER(+)/PR(+)/HER-2(+) group (n=97).All patients underwent bilateral or unilateral mammography before operation.χ²-test was used to compare the mammographic findings between TNBC group and other groups, one-way ANOVA to compare the tumor size among groups.LSD test was performed for pairwise comparison and Dunnett t₃ test was conducted to compare the onset age among groups.

Results

(1)The mean onset age was significantly different among groups (F=3.877,P=0.004), and the mean onset age of TNBC group was older than that of ER(+)/PR(+)/HER-2(+)group[(51.9±9.2) years vs (48.3±8.9)years, P = 0.020].Invasive ductal carcinoma was the main histopathological type of breast cancer in each group.(2)Compared with ER(-)/PR(-)/HER-2(+) group and ER(+)/PR(+)/HER-2(+) group, TNBC group more presented with single mass (χ²=24.808,13.628;all P＜0.005) and less frequently associated with microcalcifications (χ²=28.392,10.609;all P＜0.005).The masses were usually round or oval with indistinct margins in TNBC group [compared with ER(-)/PR(-)/HER-2(+), ER(+)/PR(-)/HER-2(-) and ER(+)/PR(+)/HER-2 (+) groups, χ² =21.328,15.035,21.556, all P＜0.005 ].The mean diameter of the masses in TNBC group was significantly larger than that in ER(+)/PR(-)/HER-2(-) group or ER(+)/PR(+)/HER-2(-) group [(23.93±11.59) mm, (18.06±5.76) mm, (20.23±7.80) mm; P=0.003,0.030).

Conclusion

The mammography of TNBC often shows single mass, round or oval, with indistinct margin, some lesions with clear margin, less associated with microcalcifications, which may be useful in mammographic diagnosis of TNBC.

Key words: Breast neoplasms, Mammography, Immunohistochemistry

Chun-xiao CUI, Qing LIN, Xiao-qing LIU, Ji-ping ZHAO, Xiao-yan TANG. Comparison of pathologic characteristics and mammographic findings between triple negative breast cancer and non-triple negative breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(05): 338-344.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2013.05.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2013/V07/I05/338

Figures/Tables 11

组别	例数	发病年龄(岁, $\bar{x}$ ±s)
TNBC组	174	51.9±9.2^a
ER(-)/PR(-)/HER-2(+)组	183	52.3±9.1
ER(+)/PR(-)/HER-2(-)组	65	54.0±11.5
ER(+)/PR(+)/HER-2(-)组	583	51.2±10.5
ER(+)/PR(+)/HER-2(+)组	97	48.3±8.9
F值		3.877
P值		0.004

组别	例数	发病年龄(岁, $\bar{x}$ ±s)
TNBC组	174	51.9±9.2^a
ER(-)/PR(-)/HER-2(+)组	183	52.3±9.1
ER(+)/PR(-)/HER-2(-)组	65	54.0±11.5
ER(+)/PR(+)/HER-2(-)组	583	51.2±10.5
ER(+)/PR(+)/HER-2(+)组	97	48.3±8.9
F值		3.877
P值		0.004

组别	例数	原位癌[例(%)]	浸润性导管癌[例(%)]	其他[例(%)]
三阴性乳腺癌组	174	19(10.92)^a	136(78.16)	19(10.92)
ER(-)/PR(-)/HER-2(+)组	183	33(18.03)^b	149(81.42)	1(0.55)
ER(+)/PR(-)/HER-2(-)组	65	5(7.69)	60(92.31)	0(0.00)
ER(+)/PR(+)/HER-2(-)组	583	61(10.46)	476(81.65)	46(7.89)
ER(+)/PR(+)/HER-2(+)组	97	3(3.09)	87(89.69)	7(7.22)
χ ²值			16.365^c
P值			0.003^c

组别	例数	X线征象[例(%)]
组别	例数	阴性	阳性
三阴性乳腺癌组	174	24(13.79)	150(86.21)
ER(-)/PR(-)/HER-2(+)组	183	16(8.74)	167(91.26)
ER(+)/PR(-)/HER-2(-)组	65	4(6.15)	61(93.85)
ER(+)/PR(+)/HER-2(-)组	583	88(15.09)	495(84.91)
ER(+)/PR(+)/HER-2(+)组	97	9(9.28)	88(90.72)
χ ²值		9.255
P值		0.055

组别	例数	X线征象[例(%)]
组别	例数	单纯肿块	单纯钙化	肿块合并钙化	局限性致密并钙化	局限性致密	结构扭曲
三阴性乳腺癌组	150	95(63.33)^ab	9(6.00)	21(14.00)	6(4.00)	18(12.00)	1(0.67)
ER(-)/PR(-)/HER-2(+)组	167	59(35.33)	36(21.56)	48(27.74)	5(2.99)	18(10.78)	1(0.60)
ER(+)/PR(-)/HER-2(-)组	61	27(44.26)	5(8.20)	14(22.95)	0(0.00)	12(19.67)	3(4.92)
ER(+)/PR(+)/HER-2(-)组	495	287(57.98)	48(9.70)	69(13.94)	8(1.62)	60(12.12)	23(4.65)
ER(+)/PR(+)/HER-2(+)组	88	34(38.64)	14(15.91)	24(27.27)	1(1.14)	12(13.64)	3(3.41)
χ ²值		41.159^c
P值		0.000^c

组别	例数	肿块类型[例(%)]		钙化情况[例(%)]
组别	例数	肿块型^a	非肿块型	钙化型^b	非钙化型
三阴性乳腺癌组	150	116(77.33)	34(22.67)	36(24.00)^c	114(76.00)
ER(-)/PR(-)/HER-2(+)组	167	107(64.07)	60(35.93)	89(53.29)	78(46.71)
ER(+)/PR(-)/HER-2(-)组	61	41(67.21)	20(32.79)	19(31.15)	42(68.85)
ER(+)/PR(+)/HER-2(-)组	495	356(71.92)	139(28.08)	125(25.25)	370(74.75)
ER(+)/PR(+)/HER-2(+)组	88	58(65.91)	30(34.09)	39(44.32)	49(55.68)
χ ²值		8.381		55.676
P值		0.079		0.000

组别	肿块数	肿块形态[例(%)]		肿块边缘[例(%)]				肿块直径(mm)
组别	肿块数	类圆形^a	分叶状和不规则形	清楚	模糊	浅分叶	毛刺	肿块直径(mm)
三阴性乳腺癌组	116	89(76.72)^bc	27(23.28)	14(12.07)^d	63(54.31)	23(19.83)	16(13.79)	23.93±11.59^f
ER(-)/PR(-)/HER-2(+)组	107	50(46.73)	57(53.27)	4(3.74)	67(62.62)	13(12.15)	23(21.50)	21.65±7.21
ER(+)/PR(-)/HER-2(-)组	41	18(43.90)	23(56.10)	4(10.00)	21(52.50)	1(2.44)	15(37.50)	18.06±5.76
ER(+)/PR(+)/HER-2(-)组	356	186(52.24)	170(47.76)	14(3.93)	181(50.84)	40(11.24)	121(33.99)	20.23±7.80
ER(+)/PR(+)/HER-2(+)组	58	39(67.24)	19(32.76)	1(1.72)	34(58.62)	10(17.24)	13(22.41)	21.81±7.11
检验值		χ ²=31.418		χ ²=15.080^e				F=4.619
P值		0.000		0.005^e				0.001

References 16

[1]	Thike AA,Cheok PY,Jara-Lazaro AR, et al.Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer[J].Mod Pathol, 2010, 23(1):123-133.
[2]	Bauer KR, Brown M, Cress RD, et al.Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer Registry[J].Cancer, 2007, 109(9):1721-1728.
[3]	Haffty BG, Yang Q, Reiss M, et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J].J Clin Oncol, 2006, 24(36):5652-5657.
[4]	曹华,闫茂生,郑涛,等.乳腺癌分子分型的临床意义[J/CD].中华乳腺病杂志:电子版,2011,5 (6):670-680.
[5]	张毅,张颖,修海清,等.三阴性乳腺癌TNM 分期的临床特点及影响预后的危险因素[J/CD].中华乳腺病杂志:电子版,2012,6(2):168-177.
[6]	Hammond ME, Hayes DF, Dowsett M, et a1.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast caner[J].J Clin Oncol,2010,28(16):2784-2795.
[7]	《乳腺癌HER2 检测指南》编写组.乳腺癌HER2 检测指南[J].中华病理学杂志,2006,35(10):631-633.
[8]	American College of Radiology ( ACR).Breast imaging reporting and data system (BI-RADS) [M].4th ed.Reston:American College of Radiology,2003:1-259.
[9]	安彦虹,叶兆祥,李弋,等.乳腺影像报告和数据系统在国人女性乳腺癌筛查中的应用价值[J].中华放射学杂志,2011,45(4):353-357.
[10]	Kojima Y,Tsunoda H.Mammography and ultrasound features of tripe-negative breast cancer[J].Breast Cancer,2011,18(3):146-151.
[11]	Ko ES, Lee BH, Kim HA, et al.Triple negative breast cancer: correlation between imaging and pathological fingdings[J].Eur Radiol,2010,20(5):1111-1117.
[12]	Evans AJ, Pinder SE,Ellis JO,et al.Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression.Nottingham Breast Team [J].Clin Radiol,1994,49(8):559-562.
[13]	Yang WT, Dryden M, Broglio K, et al.Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women[J].Breast Cancer Res Treat,2008,111(3):405-410.
[14]	Wang Y, Ikeda DM, Narasimhan B, et al.Estrogen receptornegative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression[J].Radiology,2008,246(2):367-375.
[15]	Dogan BE, Gonzalez-Angulo AM, Gilcrease M, et al.Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI [ J].AJR Am J Roentgenol,2010,194(4):1160-1166.
[16]	Uematsu T, Kasami M, Yuen S.Triple-Negative Breast Cancer: correlation between MR Imaging and pathologic findings [J].Radiology,2009,250(3):638-647.

Please choose a citation manager

Content to export